



Treating individuals with severe anaphylactic type allergic reactions

PARTICIPANT'S GUIDE





Treating individuals with severe anaphylactic type allergic reactions



PARTICIPANT'S GUIDE

Produced by:

Direction des communications of Ministère de la Santé et des Services sociaux
du Québec

This document is specifically intended for Québec health and social services
network personnel and is available solely in electronic form at:

<http://intranet.rtss.qc.ca> or www.msss.gouv.qc.ca in the **Document** section
under the heading **Publications**.

Legal Deposit

Bibliothèque et Archives nationales du Québec, 2008

Library and Archives Canada, 2008

ISBN: 978-2-550-56316-7 (PDF version)

All rights reserved for all countries. Reproduction by any means, translation, or distribution of this
document, in whole or in part, is prohibited without prior authorization of Publications du
Québec. However, partial or complete reproduction of this document for personal, non-
commercial use is permitted within Québec, on the condition that the source is credited.

© Gouvernement du Québec

Table of Contents

Foreword.....	5
Contributors.....	7
1 Introduction	9
2 Role and Responsibilities of First Aiders.....	11
2.1 Role of first aiders.....	11
2.2 Responsibilities of first aiders.....	11
2.3 Responsibilities of organizations	12
3 Physiopathology of Anaphylaxis	13
3.1 From immune reaction to anaphylaxis	13
3.2 Etiology of trigger factors	15
4 Clinical Manifestations Associated With Anaphylactic Reactions	19
4.1 Biphasic reactions	23
5 Treating Anaphylaxis With Epinephrine	25
5.1 Pharmacology	25
5.2 Administration route, doses, and storage	27
5.2.1 Safety concerns regarding the use of auto-injectors.....	27
5.2.2 Administration route	28
5.2.3 Doses.....	28
5.2.4 Storage	29
5.3 Using auto-injectors.....	29
6 Intervening in Cases of Anaphylaxis.....	31
6.1 Intervening in cases of anaphylaxis.....	31
6.1.1 Providing primary care and first aid	32
6.1.2 Identifying severe anaphylactic allergic reactions.....	33
6.1.3 Administering epinephrine.....	37
6.1.4 First aid and monitoring.....	37
6.1.5 Transport to hospital.....	38
6.2 Protocol.....	40
6.3 Special situations	41
6.3.1 Asthma and anaphylaxis.....	41
6.3.2 Using other drugs.....	42
6.3.3 Expired drug.....	43
7 Glossary	44
8 Appendix I – Using and Storing IpiPen® and Twinject™ Auto-injectors.....	45
8.1 Using the EpiPen®.....	45
8.2 Using the Twinject™	45
9 Appendix II – List of drugs	47
10 Appendix III – Pre-test	51
11 Appendix IV – Forest Worker Program - Specifics	53
12 References	55

Foreword

This document was put together with the assistance of numerous contributors in the fields of first aid, allergies, and pre-hospital emergency services (EMS).

Given the need to rapidly treat victims of serious allergic reactions, other groups of emergency responders, including first aiders, must be authorized to administer epinephrine so that it can be used even more quickly when required.

For nearly ten years now, ambulance paramedics, and more recently first responders, have been administering epinephrine in the course of pre-hospital care. Under regional EMS quality improvement programs, hundreds of cases of epinephrine use and even more cases of non-anaphylactic reactions have been reviewed. This program takes these many years of experience into account.

First aiders registering for this training must have completed CPR training (infant, child, adult) with AED. Workplace first aiders only need to have adult CPR with AED. This document will serve as a reference. Participants must read the summary document (slideshow) distributed prior to the training and complete the pretest, which must be handed in to the instructor at the start of the session. Certification is good for three years.

We wish to thank all those who helped develop and disseminate this program.

Dr. Daniel Lefrançois
National and Executive Director of EMS, MSSS
Direction adjointe des services préhospitaliers d'urgence
Ministère de la santé et des services sociaux du Québec

Dr. Colette D. Lachaine
Clinical Assistant to the National Director of EMS, MSSS
Direction adjointe des services préhospitaliers d'urgence
Ministère de la santé et des services sociaux du Québec

Contributors

WRITING

Colette D. Lachaine, MDCM
Clinical Assistant to the National Medical Director, MSSS

Pierre Bayard
Ambulance Paramedic Instructor, Collège Ahuntsic

Claude Bordeleau
Ambulance Paramedic Instructor, Montérégie Agency

CONTRIBUTORS

Québec Food Allergy Association

Table de concertation des organismes de formation en secourisme:

- St. John's Ambulance
- Commission de la santé et de la sécurité au travail
- Canadian Red Cross
- Heart and Stroke Foundation of Quebec
- Canadian Ski Patrol
- Lifesaving Society

Table des directeurs médicaux régionaux des services préhospitaliers
d'urgence

Special thanks to Dr. Daniel Rizzo

Annie Racicot, Documentation Center, MSSS

1 Introduction

Training objectives and key points

- Mission of pre-hospital emergency services
- Regulation respecting the professional activities that may be engaged in within the framework of EMS
- Definition of anaphylaxis
- Goal of the program

Mission of pre-hospital emergency services

The mission of EMS is to ensure that persons in need of pre-hospital emergency services may at all times obtain an appropriate, efficient, and quality response aimed at reducing the mortality and morbidity rate among the recipients of pre-hospital emergency services.¹

Anaphylaxis

Anaphylaxis is the most severe type of allergic reaction.

An anaphylactic reaction is a sudden, severe allergic reaction to a stimulus that affects one or more bodily systems and is accompanied by multiple signs and symptoms.¹ Anaphylactic reactions can cause serious breathing difficulties (distress), shock (circulatory failure), or both, which can be fatal. In most episodes, this is a potentially avoidable event.

To reduce complications, victims of anaphylactic reactions must be administered an injection of epinephrine (also known as adrenalin) and provided with medical care as quickly as possible. Epinephrine injected directly into muscle diminishes the intensity of the reaction, stopping or sufficiently slowing it so that the victim can get medical attention in time.

An estimated 1% to 2% of Canadians are at risk of anaphylactic reactions caused by food allergies or insect bites. In Québec, this represents as many as 140,000 people of all ages. One study found

that 84,000 cases of anaphylaxis are reported every year in the United States, 1% of which result in death.²

In fall 2006, the Office des professions du Québec tabled an amendment to the *Regulation respecting Professional activities that may be engaged in within the framework of pre-hospital emergency services and care*. This regulation lists the professional acts that are normally carried out by physicians, but that may be performed in certain circumstances by ambulance paramedics, first responders, and properly trained first aiders.

Section 3 of the regulation stipulates the following: "*In the absence of a first responder or ambulance technician, any person having received training in the administration of adrenalin approved by the regional or national medical director of pre-hospital emergency services may administer adrenalin with an auto-injection device to a person in the case of an acute anaphylactic allergic reaction.*"

This training program is for first aiders who, as a result of their training, may be required to administer epinephrine in the case of a serious anaphylactic allergic reaction.

This participant's guide, which was developed by the Direction national des services préhospitaliers d'urgence and its partners, covers the basic notions that first aiders must master to meet the training objectives. The pretest is presented in Appendix III and must be completed and handed in to the instructor at the start of the session.

2 Role and Responsibilities of First Aiders

Training objectives and key points

- Based on the roles and responsibilities of the organizations, describe the role and responsibilities of first aiders
- Identify the responses that first aiders are authorized to make

2.1 Role of first aiders

The main goal of first aiders who complete this training is to reduce morbidity (complications) and mortality (death) associated with anaphylactic reactions.

To achieve this goal, first aiders must be able to quickly recognize the signs and symptoms of an anaphylactic reaction. Once anaphylaxis has been identified, epinephrine must be administered without delay using the technique taught.

2.2 Responsibilities of first aiders

As mentioned above, this training program is intended for first aiders who, due to their accredited training, may be required to administer epinephrine in the event of a severe anaphylactic allergic reaction.

The responsibility of first aiders, who are legally protected under the Civil Code, is limited to following the protocol and keeping their knowledge up-to-date.

2.3 Responsibilities of organizations

Organizations that choose to implement a program like this are responsible for ensuring the availability of the required paediatric or adult auto-injectors at all times, and for making sure that they are replaced prior to expiration.

These organizations must also ensure that accredited first aiders keep their training up-to-date in accordance with program criteria.

In addition, they must notify the regional medical director of pre-hospital emergency services at the regional health and social services agency each time that epinephrine is used under this program.

3 Physiopathology of Anaphylaxis

Training objectives and key points

- Describe the phenomenon of sensitization
- Describe the anaphylactic reaction
- Describe the anaphylactoid reaction
- Enumerate the systems involved in an anaphylactic reaction
- Identify the most common trigger factors

3.1 From immune reaction to anaphylaxis

Most reactions by the body's immune system go unnoticed. The body discreetly defends itself against all foreign bodies (antigens), and its defensive mechanisms kick in without provoking any outwardly significant signs or symptoms.

In the case of a severe, or anaphylactic, allergic reaction, however, the immune system suddenly and explosively overreacts to a normally inoffensive substance (allergen).

Anaphylactic reactions can only occur if the person was previously exposed to the substance in question. Often, initial exposure will not cause any symptoms (sensitization). A second exposure to the allergen, however, triggers a *massive* release of histamine and other chemical substances. It is these substances that cause the signs and symptoms of an anaphylactic reaction.

Anti-allergy drugs available at your local pharmacy (Benadryl, Allegra, etc.) are anti-histamines that block histamine receptors.


The allergic cascade

1st exposure

Lymphocyte B
Differentiation
Plasmocyte
Release of IgE
Mastocytes (tissues) and basophils
peripheral blood)

2nd exposure

Allergens
Allergy mediators
Inflammatory allergic reaction:
eosinophils and lymphocytes
Allergic reaction



Allergic cascade of an anaphylactic reaction
This diagram has been adapted by the Québec Food Allergy Association.

Anaphylactoid reactions are clinically similar to anaphylactic reactions. They are accompanied by the same signs and symptoms, and the same substances are released into the blood stream.

The underlying phenomenon, however, is totally different. Anaphylactoid reactions are not immune reactions. Unlike anaphylactic reactions, they do not require previous contact with the substance. Since the two types of reaction are clinically impossible to tell apart, they are treated the same way.

So do not worry whether the patient has been previously exposed to the suspected allergen.

Histamine and the other chemical substances that are produced cause the blood vessels (veins) to dilate. As a result, they become more

“porous” (permeable), which means that the liquid (blood) they normally contain can escape more easily. This is what causes the swelling often associated with allergic reactions.

Trigger Factors

It is important for first aiders to be familiar with anaphylaxis triggers. In an emergency situation, trigger factors must be identified or strongly suspected before adrenalin is administered.

They also make muscles in the respiratory tract tighten up (bronchospasm) and increase the production of bronchial secretions, causing respiratory problems that resemble an asthma attack.

These substances are released throughout the body, which is why an anaphylactic reaction can affect all of the following systems:

- Respiratory system
- Cardiovascular system
- Gastro-intestinal system
- Skin

In the next chapter, we will explain how these chemical substances cause the different signs, symptoms, and complications linked to anaphylactic reactions.

3.2 Etiology of trigger factors

Anaphylactic reactions are caused by a wide variety of trigger factors, but some are more common than others. In the event of an anaphylactic reaction, it is important for first aiders to identify the potential trigger substance. The presence of a **causal agent** is a key element in deciding whether to administer epinephrine or not.


The most common trigger factors are food, insect bites, and drugs. In Canada, the most common

food triggers are peanuts, nuts (almonds, cashews, pistachios, and others), milk, eggs, fish, shellfish and molluscs, and to a lesser extent, sesame seeds, soy, and wheat.⁴ Most food allergens tend to cause respiratory distress.⁵



In the case of insect bites, hymenoptera (bees, wasps, and ants) are the most frequently identified culprits. Shock is the most common anaphylactic reaction to bites and stings.⁶

Other trigger factors include certain drugs and pharmaceutical products. Antibiotics, acetylsalicylic acid (Aspirin), non-steroidal anti-inflammatory (NSAID), and intravenous contrast agents (substances injected for certain radiological exams) are the ones most often associated with anaphylactic and anaphylactoid reactions.



Latex has attracted a great deal of attention, but it is rarely associated with anaphylactic reactions

(over a ten-year period in England, no deaths were linked to proven latex exposure).⁷

In certain people, a violent effort made after eating a normally inoffensive food can occasionally trigger an anaphylactic reaction. In others, a violent effort alone may be enough to cause such a reaction.⁷

Lastly, in certain situations (up to 5%), the trigger factor remains unknown.⁷ Some studies place this figure even higher.

ANYPHLAXIS TRIGGERS	
CATEGORIES	TRIGGER FACTORS
Food Foods are the most common triggers.	<ul style="list-style-type: none"> ▪ Peanuts, nuts (almonds, cashews, pistachios, and others), milk, eggs, fish, shellfish and molluscs, and to a lesser extent, sesame seeds, soy, and wheat
Biting insects	<ul style="list-style-type: none"> ▪ Bees, wasps, and ants
Drugs	<ul style="list-style-type: none"> ▪ Antibiotics, acetylsalicylic acid (Aspirin), non-steroidal anti-inflammatories (NSAID), and intravenous contrast agents

4 Clinical Manifestations Associated With Anaphylactic Reactions

Training objectives and key points

- Recognize the signs and symptoms of a serious anaphylactic reaction
- Identify the factors that can influence the severity of an anaphylactic reaction
- Describe the secondary (biphasic) reaction

Anaphylactic reaction

Anaphylactic reactions affect a number of systems. The speed of the reaction may vary from one episode to another. **Anaphylactic reactions are unpredictable.**

Severity of the reaction

The faster the signs and symptoms appear, the more severe the reaction will be.

Anaphylaxis is a severe allergic reaction affecting one or more systems of the human body. **It is not a localized reaction.**

Anaphylactic reactions usually occur within the first two hours of exposure to the trigger factor. Normally, the signs and symptoms develop quickly and reach maximum intensity within approximately 30 minutes.⁴ Sometimes, the reaction occurs several hours after exposure. This is rare. In exceptional circumstances, cardiopulmonary arrest can occur during the first few minutes of the reaction.¹⁴

Anaphylactic reactions are unpredictable. The speed with which the signs and symptoms develop in the same person can vary significantly from one episode to another.

The main manifestations are associated with the respiratory, circulatory, and gastro-intestinal systems and the skin. The following table lists the main signs and symptoms of anaphylactic reactions.

SIGNS AND SYMPTOMS ASSOCIATED WITH ANAPHYLACTIC REACTIONS	
SYSTEM	SIGNS AND SYMPTOMS
Respiratory	<ul style="list-style-type: none"> ▪ Difficult and/or noisy breathing (wheezing), choking sensation, persistent cough, hoarseness, bluish skin (cyanosis), nasal congestion or hay fever-like symptoms, difficulty swallowing, change in crying among infants
Cardiovascular	<ul style="list-style-type: none"> ▪ Rapid and weak pulse, paleness, cold sweat (diaphoresis), bluish skin (cyanosis), changes in consciousness, dizziness
Gastro-intestinal	<ul style="list-style-type: none"> ▪ Nausea, abdominal pain or cramps, vomiting, diarrhoea
Skin	<ul style="list-style-type: none"> ▪ Weals (hives), itchiness, localized swelling (angiooedema) and redness
Other signs and symptoms	<ul style="list-style-type: none"> ▪ Anxiety, sense of imminent death, headache and, in women, uterine cramps

Generally speaking, the faster the signs and symptoms appear, the more severe the reaction will be.⁷

Deaths associated with anaphylactic reactions are caused by respiratory distress (swelling and obstruction of the airways, or bronchial constriction) or shock (drop in blood pressure).

The following table shows how frequently the signs and symptoms of anaphylaxis manifest themselves. It is important to note that none of these signs and symptoms are found in all situations. First aiders must therefore assess the status of the victim every time they are called into action to determine whether the victim is having an anaphylactic reaction.

CLINICAL SIGNS AND SYMPTOMS	FREQUENCY (%)
<ul style="list-style-type: none"> ▪ Hives and angiooedema 	80 to 89
<ul style="list-style-type: none"> ▪ Swelling of the upper airways 	50 to 59
<ul style="list-style-type: none"> ▪ Difficulty breathing ▪ Severe erythema (skin redness) 	40 to 49
<ul style="list-style-type: none"> ▪ Dizziness, loss of consciousness, drop in blood pressure ▪ Nausea, vomiting, diarrhoea, abdominal cramps 	30
<ul style="list-style-type: none"> ▪ Headache ▪ Nasal discharge ▪ Chest pain ▪ Itchiness ▪ Convulsions 	29 or less

Adapted from a table in American Family Physician, A Practical Guide to Anaphylaxis, 2003, p. 1326.

Headaches, nasal discharge, chest pain, and convulsions are non-specific symptoms that occasionally accompany serious anaphylactic reactions. Occurring on their own, they should not be considered as signs of anaphylaxis.

Signs of anaphylaxis



Urticaria

Source : <http://www.4-men.org/images/hives.jpg>

The severity of anaphylactic allergic reactions can vary depending on the quantity of allergen, the exposure pathway (injection vs. ingestion), and the number of repeat exposures to the allergen.

4.1 Biphasic reactions

In 5% to 23% of anaphylaxis cases, signs and symptoms reappear later on despite their decrease or disappearance after treatment.⁷ Usually, the signs and symptoms of the second attack are similar to the first. This second reaction can take place anywhere from 1.8 to 28 hours after the initial one.

The literature shows that secondary reactions especially occur when there were delays in administering the epinephrine.

It is for this reason, among others, that victims of an anaphylactic reaction must quickly be administered epinephrine, and **subsequently assessed by a doctor, even if their condition improves.**

5 Treating Anaphylaxis With Epinephrine

Training objectives and key points

- List the effects of epinephrine
- Demonstrate the safe use of the auto-injector
- Select, based on the patient’s weight, the appropriate dose
- Describe how to store the auto-injector
- Apply the five “Rs” for the administration of epinephrine



Epinephrine, also known as **adrenalin**, is the *first-line* drug for treating severe anaphylactic allergic reactions (anaphylaxis).

5.1 Pharmacology

Epinephrine is the drug of choice for treating anaphylaxis. The more quickly it is administered, the less severe the immediate allergic reaction will be.

The main effects of epinephrine are as follows:

Therapeutic effects of epinephrine (adrenalin)	
<ul style="list-style-type: none"> ▪ Constricts blood vessels ▪ Increases the contraction force of the heart ▪ Increases the heart rate 	Increases blood pressure
<ul style="list-style-type: none"> ▪ Dilates the bronchi and bronchioles 	Provides relief from asthma symptoms

It is important to know that epinephrine only provides temporary relief. Because of this, the patient should be monitored closely for any deterioration in signs or symptoms or the reappearance of the allergic reaction. The first aider or an onlooker should call 9-1-1 as quickly as

possible after administering epinephrine using an auto-injector.

The rapid administration of epinephrine can prevent death as well as biphasic reactions.⁸ Because of this, as soon as the first aider decides that the person is suffering from an anaphylactic reaction, he or she must immediately administer epinephrine. [3]

In many cases, when an anaphylactic reaction leads to death, epinephrine was either not administered or was given too late. [8]

In situations of anaphylaxis, there is no reason (contra-indication) not to administer epinephrine. On the other hand, when the situation is not clear, care must be taken when administering epinephrine to elderly patients and to patients with cardiovascular diseases (angina, myocardial infarction).

These patients have a higher risk of complications following the administration of epinephrine. However, when it is clear that an individual is suffering from an anaphylactic reaction, you should always administer epinephrine, even to these patients.

The most common side effects of epinephrine are palpitations, anxiety, tremors, nausea, vomiting, dizziness, sweating, fast heartbeat, and hypertension. Potential complications include arrhythmias (ventricular tachycardia, ventricular fibrillation), angina, myocardial infarcts, and heart attack. These major complications are very rare with intramuscular injections.

5.2 Administration route, doses, and storage

5.2.1 Safety concerns regarding the use of auto-injectors

First aiders are authorized to administer epinephrine using auto-injectors. Auto-injectors are glass cartridges that look like a large pencil and that contain a pre-measured dose of drug. When the tip is pressed against the body (usually the thigh), the mechanism automatically triggers the release of the concealed needle and injects the drug. Once triggered, the needle remains exposed.

The risks related to the use of auto-injectors are mainly those associated with the first aider administering the dose.

Once the auto-injector has been used and the needle exposed, first aiders must take care not to prick themselves with the needle. While accidental contact with the soiled needle carries little risk, there still is potential for contamination.

To eliminate the risk of accidental injection, first aiders must immediately place the auto-injector securely in its case after administering the dose. Auto-injectors should never be thrown into the garbage can.

Contaminated auto-injectors (in their cases) should be given to the ambulance paramedics for safe disposal in the appropriate container.

Another potential danger of using auto-injectors is accidental injection of epinephrine into the

thumb (or other finger) by the first aider. The transmission of blood-borne diseases is not a major concern in this case because the needle is "clean."

However, epinephrine causes blood vessels to constrict (vasoconstriction) severely. When injected into a finger, the vasoconstriction is so severe that blood circulation in the finger may stop completely. If circulation shuts down for too long, it can theoretically lead to necrosis and loss of the finger. The finger quickly becomes white and cold.

When epinephrine is injected into a finger, the first aider must immediately go to a hospital with the patient to receive the appropriate treatment. If possible, the arm should be kept in a downward position and the finger covered with warm compresses.

5.2.2 Administration route

The EpiPen® and Twinject™ auto-injectors administer drugs directly into the muscle (intramuscular). This is better than injecting a drug under the skin (subcutaneous) because it enables the epinephrine to enter the blood stream more quickly.

5.2.3 Doses

First aiders have to choose between two auto-injectors, depending on the weight of the patient. The paediatric auto-injector administers 0.15 mg of epinephrine intramuscularly while the adult version administers 0.30 mg.

While manufacturers do not recommend administering paediatric doses to children weighing less than 15 kg, Canadian recommendations (for pharmacists) recommend administering paediatric doses to children weighing up to 22 kg.

5.2.4 Storage

Auto-injectors must be stored in an accessible, unlocked location, for example, the first aid kit. In emergencies, they must be quickly accessible.

Based on the manufacturers' recommendations for ensuring the efficacy of the drug, auto-injectors must be stored under specific conditions.

Generally speaking, auto-injectors must be stored in their carrying cases at room temperature (20 to 25°C). During outings, however, epinephrine can tolerate temperatures ranging from 15°C to 30°C.

Auto-injectors must be kept from freezing (do not refrigerate) and in the dark. If the drug freezes, it must be replaced (according to the manufacturers' recommendations).

5.3 Using auto-injectors

Administering a drug involves certain responsibilities. When administering epinephrine, first aiders must verify the five "Rs":

- **Right patient:** First aiders must make sure that the inclusion criteria (symptoms of anaphylaxis) are present before administering epinephrine.

- **Right drug:** EpiPen® and Twinject™ auto-injectors only inject epinephrine (1:1,000¹). First aiders must verify the expiry date of the auto-injectors and ensure that the drug is clear and contains no precipitate.
- **Right dose:** First aiders must choose the right auto-injector based on the patient's weight, i.e., 0.15 mg or 0.30 mg of epinephrine.
- **Right time:** As soon as the decision is taken to administer epinephrine, the first dose must be given immediately. A second dose may be given fifteen (15) minutes later if the symptoms persist.
- **Right administration route:** In the present context (auto-injectors), the epinephrine must be injected intramuscularly in the fleshy part of the thigh. The detailed technique is described in Appendix I.

¹ Epinephrine (adrenalin) 1:1000 is diluted by adding 1 part drug to 1,000 parts water.

6 Intervening in cases of anaphylaxis

Training objectives and key points

- Identify the patient who is to receive the epinephrine (inclusion criteria)
- Describe each step of the intervention protocol
- Determine whether a second dose must be administered
- List the clinical information that must be provided to ambulance paramedics
- Describe how asthma can exacerbate the anaphylactic reactions
- Use an auto-injector in situations involving severe allergic reactions (anaphylaxis)

6.1 Intervening in cases of anaphylaxis

When confronted with an anaphylactic reaction, first aiders must quickly identify the reaction and immediately administer epinephrine.

An English study reviewing 164 deaths caused by anaphylactic reactions reported that the average time between contact with the allergen and cardiopulmonary arrest in these cases was 30 minutes when the patients ingested the allergen, and 15 minutes in the case of venom.^[14] The study noted that only 20% of these victims had been administered adrenalin prior to their deaths. This was due to one of two factors: lack of availability of the drug or lack of time to respond to a rapid, severe reaction.

It is important to understand that epinephrine is of no use in the event of cardiopulmonary arrest. The lack of effective blood circulation (under ideal conditions, cardiac massage provides approximately 25–30% of the normal blood flow) does not allow the drug to spread throughout the body.

To facilitate emergency interventions involving individuals with severe anaphylactic allergic reactions, the various steps have been divided into five groups:

- Providing primary care and first aid
- Identifying the inclusion criteria
- Administering epinephrine
- Providing first aid and monitoring the patient
- Taking the patient to a hospital

6.1.1 Providing primary care and first aid

First aiders must adopt a **safety-first approach**, including evaluating the environment and the risks for their own safety.

First aiders must also apply the principles of **universal protection**:

- Be especially careful in the presence of open wounds or with potentially infected persons.
- Wear gloves.
- When applicable, immediately and safely dispose of contaminated sharp objects.
- Wash hands thoroughly after the intervention.

If the patient is in an altered mental state, first aiders must take a primary approach by opening the airways, ensuring effective oxygenation (administer oxygen if available), and checking for signs of circulation.

In such situations, it is also important to move the patient as little as possible. Unless there are signs of severe respiratory distress, when it is best to

keep patients seated, patients should be rolled on their side in the recovery position.

If another first aider is present, **emergency medical services (911) must be called immediately**. Under exceptional circumstances, if the first aider is alone, he or she must administer epinephrine first before calling the emergency services.

6.1.2 Identifying severe anaphylactic allergic reactions

After the primary approach, first aiders must determine whether the patient is suffering from a severe anaphylactic allergic reaction. The first aider is faced with two possible situations; the patient is either allergic/anaphylactic or is not.

Patients known to be allergic

First aiders must talk to the patient to know whether he or she has a history of anaphylactic reactions. If the patient is in an altered mental state, first aiders must ask close family members or friends or check whether the patient is wearing a medical ID bracelet (e.g., MedicAlert®).

If the patient has a history of anaphylactic reactions, epinephrine must be administered using an auto-injector **at the first sign** of an allergic reaction when the patient has been or is suspected of having been in contact with an allergen.

The allergen does not have to be the same allergen that caused previous reactions.

Patients not known to be allergic

As mentioned above, it is possible that an individual may have an anaphylactic reaction with no previous history of such reactions.

In patients with no history of anaphylactic reactions, epinephrine can be administered when two conditions are present. First, the **causal agent** (stimulus that may have triggered the reaction) must be identified (or strongly suspected). The patient must have been in contact with the allergen in the 12 hours preceding the reaction. Second, the first aider must recognize the **signs and symptoms of a severe anaphylactic allergic reaction**.

In the case of causal agents, one of the following three factors is sufficient to administer epinephrine:

- **Respiratory distress**
 - Visibly difficult, laboured breathing
 - Wheezing
 - Bluish skin (cyanosis)

- **Circulatory failure (shock)**
 - Loss of consciousness (fainting or syncope)
 - Severe weakness
 - Cold sweat (diaphoresis)
 - Rapid pulse (tachycardia)
 - Altered mental state

Visible swelling of the tongue

The presence of skin lesions is not an inclusion criterion for the protocol since they may not occur during an anaphylactic shock.

There are no contra-indications (exclusion criteria) to the use of epinephrine in the case of severe allergic reactions (anaphylaxis).

If the causal agent has been identified or strongly suspected, and one of the three factors described above is present, first aiders must immediately administer epinephrine.

In certain situations, first aiders may be unable to identify the causal agent. Nevertheless, the environment or context may provide important information.

Example of a problematic scenario

You are a first aider in your workplace and you are called on to deal with a person in the cafeteria who is having serious difficulty breathing. When you arrive, you note that she has trouble answering questions and shows clear signs of respiratory distress. Her face is also swollen. Her colleagues tell you that she had begun her meal but you check and you eliminate choking as a possible explanation.

In the context of the preceding scenario, there is not enough information for the first aider to make a definitive decision. However, in light of the signs of respiratory distress and the fact that the airways were not obstructed by a foreign body, it

would be appropriate to administer epinephrine given the cutaneous symptoms (swollen face).

Context allergy-environment

- Environment (restaurant, cafeteria)

As mentioned above, if it is difficult to determine the causal agent and the patient shows signs of an anaphylactic reaction while eating (or has eaten within the preceding hour), contact with a causal agent may be suspected.

- New drug

Like a recent meal, an anaphylactic reaction may appear when someone takes a new drug, even if the person is not known to be allergic to this drug.

- Noisy breathing (not corrected by opening the airways) with unconsciousness

When a person is unconscious and anaphylaxis is possible, the first aider must consider the possibility of an anaphylactic reaction when the patient's respiration remains noisy, even after her airways have been opened using the "head tilt – chin lift" technique.

- Medical ID bracelet (e.g., MedicAlert®)

Medical ID bracelets such as MedicAlert® provide vital information to first aiders when a patient is unable to speak or is unconscious.

6.1.3 Administering epinephrine

Once a severe allergic reaction (anaphylaxis) has been identified, epinephrine must be administered immediately.

The dose depends on the patient's weight. If the patient weighs **less than 25 kg**, **0.15 mg** must be administered. If he or she weighs **25 kg or more**, an adult dose (**0.30 mg**) must be administered.

Immediately after an injection, first aiders must **safely dispose of the auto-injector** to avoid accidentally stabbing themselves with a potentially contaminated needle.



First aiders must record the time the epinephrine was administered. This information will be important for all other responders who may be called on to help. It is thus vital that this information be given to the ambulance paramedics.

The time at which the first dose was administered will also enable you to re-evaluate the patient periodically in order to decide whether a second dose of epinephrine is needed.

6.1.4 First aid and monitoring

When epinephrine has been administered and the auto-injector has been safely discarded, first aiders must continue with first aid measures.

First, if alone, the first aider must **contact the EMS (911)**. If two first aiders are present, one must simply make sure that the call has been correctly made.

If the patient's mental state is altered, first aiders must continue with **the primary approach (ABC)**.

If the first aiders have access to a source of oxygen, but have not yet given it, they must do so now, **at the highest concentration possible**.

First aiders must continue monitoring the patient's condition in order to decide whether a second dose of epinephrine is needed.

A second dose of epinephrine must be administered if the patient still has inclusion criteria fifteen (15) minutes after the first dose. There is no set maximum number of injections.

A different injection site should be used for each dose.

6.1.5 Transport to hospital



Even if the patient's condition has improved, he or she must **always** be taken to a hospital by ambulance for a medical evaluation. The unpredictable nature of anaphylactic reactions, biphasic reactions, and the administration of epinephrine are sufficient reason to justify a medical evaluation.

When the paramedics take charge of the patient, the first aiders must provide the following clinical information:

Clinical information to give to the paramedics

- **Inclusion criteria** (including the causal agent)
- **Number of injections and the dose administered**
- **Time** of administration
- **Changes** in signs and symptoms caused by the drug

6.2 Protocol

1. Safety evaluation

- a. Evaluate the safety of the scene
- b. Wear gloves

2. Primary approach and first aid

- a. Is the patient conscious or unconscious?
- b. **A-Airway:** Is the patient's airway blocked?
 - i. Open the airways, if needed.
- c. **B-Breathing:** Is the patient breathing?
 - i. If so, deliver the highest concentration of oxygen available.
 - ii. If not, begin ventilating the patient.
- d. **C-Circulation:** Does the patient present signs of circulation??
 - i. If not, begin CPR*.
- e. If a second first aider is present, call 911.
- f. If the patient is unconscious, roll him/her on his/her side in the recovery position.

3. Identify the inclusion criteria

- a. Patient known to be allergic/anaphylactic
 - i. Recent contact with a known or suspected allergen AND
 - ii. Showing the first signs of an allergic reaction
- b. Patient not known to be allergic/anaphylactic
 - i. Recent contact with a known or suspected allergen AND
 - ii. One or more of the following situations
 - Respiratory distress
 - Circulatory failure
 - Visible oedema (swelling) of the tongue

4. Administer the appropriate dose of epinephrine, if indicated

- a. Using the technique you have been taught (in the thigh)
- b. Discard the auto-injector safely

5. Monitoring and first aid

- a. Deliver oxygen at the highest concentration possible, if available.
- b. Call EMS (911), if the first aider is alone.
- c. Monitor changes in signs and symptoms.

- d. Re-evaluate the inclusion criteria every 15 minutes; if present, administer another dose of epinephrine.

6. Transport to hospital

- a. Give the ambulance paramedics the following information:
 - i. Inclusion criteria
 - ii. Number and doses administered
 - iii. Time administered
 - iv. Evolution of the patient

NOTE

* If the patient is having a heart attack, the epinephrine protocol should not be used.

Doses:

- Patient weighing less than 25 kg: Epinephrine 0.15 mg
- Patient weighing 25 kg or more: Epinephrine 0.30 mg

Maximum number of doses:

Administer epinephrine Q15 minutes for as long as the inclusion criteria are present and you have a supply of the drug.

6.3 Special situations

6.3.1 Asthma and anaphylaxis

People who have asthma and who have been diagnosed with anaphylaxis in the past are more likely to suffer from severe respiratory problems during an anaphylactic reaction.

When an anaphylactic reaction is suspected, but you are not sure whether it is just as asthma

attack, you must administer epinephrine if the person meets the inclusion criteria for anaphylaxis.

6.3.2 Using other drugs

For severe anaphylactic allergic reactions, epinephrine remains the drug of choice. It is the only drug that can be administered by first aiders. The patient may wish to take another drug such as an antihistamine, a bronchodilator (pump), or cortisone.

If an attending physician has prescribed the drug, the first aider must let the patient take it. It should be remembered that these drugs act on a single chemical receptor at a time. They are thus not as effective as epinephrine in treating anaphylaxis. **Priority should be given to epinephrine, which remains the first-line medication.**

6.3.3 Expired drug

If the only auto-injector available is past its expiry date, use it anyway because the drug will probably still retain some of its efficacy.

7 Glossary

Glossaire

- **Angioedema:** A localized swelling of subcutaneous tissues and mucosa caused by an increase in the permeability of capillaries.
- **Antibody:** Protein produced by plasmocytes in response to an antigen that attaches to the antigen to neutralize it.
- **Basophil granulocytes:** White blood cells (leucocytes) that contain histamine and cytokines; similar to mast cells (mastocytes).
- **Biphasic reaction:** Recurrence of signs and symptoms of anaphylaxis following the resolution of the crisis.
- **Cyanosis:** Blue coloration of the skin (extremities), tongue, and lips due to a lack of oxygen.
- **Diaphoresis:** Excessive cold sweating.
- **Histamine:** Natural amine found in mast cells and other cells throughout the body that, when released, causes dilation of the capillaries and contraction of smooth muscles.
- **Mast cells:** Immune cells that reside in several types of tissue; mast cells detect foreign cells and trigger a local inflammatory reaction against them; they are especially numerous in skin submucosal tissues in the airways and gastrointestinal tract.
- **Neutrophil granulocytes:** White blood cells with a multilobulated nucleus and intracytoplasmic granules that have no affinity for acid or basic stains.
- **Stridor:** High pitched (usually inspiratory) sound, secondary to upper airway obstruction.
- **Urticaria:** Skin condition characterized by raised red wheals that are generally raised and pruritic (itchy) and that can occur anywhere on the body.
- **Wheezing:** Audible, respiration described as a high-pitched, musical sound and caused by a narrowing or obstruction of the bronchioles.

8 Appendix I – Using and Storing EpiPen® and Twinject™ Auto-injectors

Training objectives and key points

- Learn how to administer the drug using both types of auto-injectors

8.1 Using the EpiPen®

Following are detailed instructions on how to use the EpiPen®.



1. Unscrew the yellow or green cap and remove the auto-injector from its storage tube.

2. Grasp the auto-injector with the black tip pointing downward.

3. Remove the grey safety release.



4. Hold the black tip against the outer thigh and jab firmly to activate the auto-injector. Hold in place for

5. approximately 10 seconds, then remove.

6. Massage injection area for 10 seconds.

8.2 Using the Twinject™

STEP 1: PREPARING THE AUTO-INJECTOR


Check the Twinject 0.3 mg or Twinject 0.15 mg auto-injector regularly. The drug may not be effective if the solution is cloudy (contains particles), rose-coloured or a yellow that is darker than clear yellow, or the expiration date has passed.

In the event of a life-threatening allergic reaction, you should use an out-of-date auto-injector, if that is all you have.

Do NOT remove the GREEN caps until you are ready to use the Twinject.

STEP 2: FIRST DOSE

1. Pull off the **GREEN (1)** end cap. You will now see a RED tip. **Never put thumb, finger, or hand over the RED tip.**



2. Pull off the second **GREEN (2)** end cap.



3. Put the RED tip against the middle of the outer thigh (the needle can go through clothing).



4. Press down firmly until the mechanism is triggered. Hold in place while slowly counting to 10.
5. Remove the auto-injector from your thigh and check the RED tip. If the needle is exposed, you have received the dose. If not, repeat steps **3** and **4**

NOTE: Only the first dose delivered by the Twinject can be used during the program. The regulation governing professional activities specifies that epinephrine must be administered using an auto-injector.

9 Appendix II – List of drugs

List of commonly encountered nonsteroidal anti-inflammatory drugs (NSAID) and antibiotics

The names of the drugs on the left are their generic names, while the names on the right are those given by the pharmaceutical companies that manufacture them. The suffixes Apo-, Gen-, Novo-, Nu-, etc. refer to the pharmaceutical companies that produce the drugs. For example: Apo- refers to APOTEX.

This list is not exhaustive. Only the most commonly encountered drugs have been listed. The names of some companies have been omitted because the name of the drug is composed of the suffix and the generic name.

If a patient is known to be allergic to ASA, he or she must be considered as being allergic to all ASA derivatives and all NSAIDs.

If a patient is known to be allergic to an antibiotic, he or she must be considered as being allergic to all antibiotics in the same class.

1. NSAIDs

Salicylic acid derivatives

ASS (acetylsalicylic acid) – Aspirin

The following products contain ASA.

ASA
Aggrenox
Alka-seltzer
AAS
Asaphen
Aspirin
Entrophen
Fiorinal
Midal
Novasen

	Percodan
	Ratio-oxycodon
	Robaxisal
	Trianal
	222
Diflunisal	Dolobid
Sulfasalazine	Salazopyrin
Other NSAIDs	
Celecoxib	Celebrex
Diclofenac	Apo-Diclo
	Arthotec
	Novo-Difenac
	Voltaren
Etodolac	Apo-Etodolac
Flurbiprofen	Ansaid
	Froben
Ketolorac	Toradol
Ibuprofen	Advil
	Motrin
	Robax Platinum
Indomethacin	Apo-indomethacin
	Indocid
	Novo-methacin
	Nu-Indo
Naproxen	Anaprox
	Naprosyn
Meloxicam	Mobicox
Sulindac	Apo-sulin
	Novo-Sudac

2. Antibiotics

Cephalosporins

Cefaclor	Ceclor
Cefadroxil	Duricef
Cefixime	Suprax
Cefprozil	Cefzil
Cefuroxime	Ceftin
Cephalexin	Keflex
	Novo-Lexin

Macrolides

Azithromycin	Zithromax Z-pak
Clarithromycine	Biaxin
Erythromcyin	EES Eryc Novo-Rythro PCE Pediazole (Erythro + Sulfa)

Penicillins

Amoxicillin	Amoxil Novamoxin Clavulin (Amoxil + clavulnic acid)
Cloxacillin	Apo-Cloxi Novo-Cloxin Nu-Cloxi
Penicillin V	Apo-Pen VK Novo-Pen VK
Pivampicillin	Pondocillin

Quinolones

Ciprofloxacin	Cipro
Levofloxacin	Levaquin
Moxifloxacin	Avelox
Norfloxacin	Apo-Norflox
Ofloxacin	Floxin

Sulfonamides

Sulfamethoxazole + trimethoprim	Apo-Sulfatrim Bactrim Novo-Trimel Nu-Cotrimox Septra
---------------------------------	--

Tetracyclines

Doxycycline	Doxycin Novo-doxilin Vibra-Tabs
Minocycline	Enca Minocin
Tetracycline	Apo-Tetra Nu-Tetra

Others

Clindamycin	Dalacin C
Metronidazole	Flagyl
Nitrofurantin	MacroBid
Nitrofurantoin	Macrodantin
Rifampin (in the Québec drug list)	Rifadin Rofact

10 Appendix III – Pre-test

1. **What is anaphylaxis?**
 - a) A local allergic reaction
 - b) A generalized allergic reaction
 - c) A very severe allergic reaction
 - d) Is not an allergic reaction

2. **What are the substances that most often cause anaphylaxis?**
 - a) Pollen, grass, and bees
 - b) Animals, acarians, and drugs
 - c) Animals, pollen, and grass
 - d) Bees, drugs, and certain foods

3. **The following signs and symptoms are typical of an anaphylactic reaction, except for one. Which one?**
 - a) Severe difficulty breathing
 - b) Shock
 - c) Swelling of the tongue
 - d) Red eyes

4. **What is the first-line drug for treating an anaphylactic reaction?**
 - a) Epinephrine
 - b) Benadryl
 - c) Cortisone
 - d) Cimetidine

5. **What dose of epinephrine must be administered to a child weighing 20 kg?**
 - a) 0.15 mg
 - b) 0.30 mg
 - c) 0.03 mg
 - d) 0.015 mg

6. **What does of epinephrine must be administered to a child weighing 30 kg?**
- a) 0.15 mg
 - b) 0.30 mg
 - c) 0.03 mg
 - d) 0.015 mg
7. **When should epinephrine be administered to a patient who has already had an anaphylactic reaction?**
- a) When he become unconscious
 - b) When he shows signs of respiratory distress, shock, or swelling of the tongue after being exposed to a known allergen
 - c) At the first sign of an allergic reaction
 - d) When he has trouble breathing
8. **When should epinephrine be administered to a patient who has never had an anaphylactic reaction?**
- a) When he become unconscious
 - b) When he has trouble breathing
 - c) At the first sign of an allergic reaction
 - d) When he shows signs of respiratory distress, shock, or swelling of the tongue after being exposed to a known allergen
9. **In the event of an anaphylactic reaction and the first aider is alone, when should he call emergency services (911)?**
- a) When he realizes that the patient is unconscious
 - b) When a second first aider shows up
 - c) After administering epinephrine
 - d) When he realizes that it is an anaphylactic reaction
10. **What are the immediate dangers (2) of using an auto-injector?**
- a) An infection at the injection site
 - b) Accidental injection of epinephrine in the finger
 - c) Accidental stabbing of the responder with a contaminated needle
 - d) Profuse bleeding at the injection site

11 Appendix IV – Forest Worker Program - Specifics

Background

The epinephrine administration program for forest workers was set up in the 1990s, even before the pre-hospital services program.

Regional public health teams composed of occupational health and safety nurses and physicians, in collaboration with the CSST, have run the program since its inception. Insect bites are the only causal agents that are taken into consideration in this program.

The program will have to be harmonized with the provisions of the new Regulation. However, the special context of forest workers must be taken into consideration when training is provided to them.

Specifics

When training is provided to forest workers, the following elements must be adapted to their particular situation:

- The definition of forest worker is as follows: The worker must be more than 30 minutes from emergency pre-hospital services.
- Forest workers are advised not to wear jewellery and thus do not wear MedicAlert bracelets. They are therefore encouraged to notify fellow workers of their medical status and allergies, if any.
- Since the pants worn by forest workers are thicker, for better protection against chain saw injuries, the needle of the auto-injector may not penetrate through to the muscle of the thigh.

Because of this, the pants must be pulled down to inject the epinephrine into the bare thigh.

- The principles set out in the guide for evacuating and transporting injured forest workers must be followed when contacting emergency pre-hospital services (EMS); 911 must not be used to contact EMS.

12 References

Documents

Québec Food Allergy Association – Guide (French only)
Paramedic Textbook

Articles

2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care, Part 10.6: Anaphylaxis, *Circulation*, 2005, 112, IV-143-IV-145.

Walker S., Sheik H., Editorial, Managing anaphylaxis: effective emergency and long-term care are necessary, *Clinical & Experimental Allergy*, 2003, 33: 1015-1018.

McLean-Tooke P.C.A., Bethune C.A., Fay, A.C., Spickett G.P., Adrenalin in the treatment of anaphylaxis: what is the evidence, *British Medical Journal*, 2003, 327: 1332-1335.

Fogg M.I., Pawlowski N.A., Anaphylaxis, *Pediatric Case Reviews*, 2003, Vol. 3(2): 72-82.

Lieberman, P., Use of epinephrine in the treatment of anaphylaxis, *Current Opinion in Allergy & Clinical Microbiology*, 2003, 313-318.

Yunginger J.W., Sweeny K.G., Sturner W.Q., Giannandrea L., Teigland J.D., Bray M., Benson, P.A., York J.A., Biedrzycki L., Squillace D.L., et. al., Fatal food-induced anaphylaxis, *Journal of the American Medical Association*, 1988, 260(10): 1450-1452.

Sampson H.A., Anaphylaxis and Emergency Treatment, *Pediatrics*, 111: 1601:1608.

Estelle F., Simons R., *Journal of Allergy and Clinical Immunology*, 113(5): 837-844.
Tang A.W., A Practical Guide to Anaphylaxis, *American Family Physician*, 2003, 68(7): 1325-1332.

Hughes G., Fitzharris P., Managing acute anaphylaxis, *British Medical Journal*, 1999, 319: 1-2.

Vilke G.M., Case Conferences, Food-dependent exercise-induced anaphylaxis, *Prehospital Emergency Care*, 2002, 6(3): 348-350.

Johnston S.L., Unsworth J., Gompels M.M., Lesson of the week, Adrenalin given outside the context of life threatening allergic reactions, *British Medical Journal*, 326: 589-590.

Pumphrey R.S., Lessons for management of anaphylaxis from a study of fatal reactions, *Clinical and Experimental Allergy*, 2000, 30:1144-1150.

Fitzharris P., Empson M., Ameratunga R., Sinclair J., Crump V., Steele R., Broom B., Anaphylaxis management: the essential role of adrenalin (epinephrine) auto-injectors. Should PHARMAC fund them in New Zealand? *The New Zealand Medical Journal*, 2006, Vol. 119, No. 1233.

Cone D., Subcutaneous Epinephrine for Out-of-Hospital Treatment of Anaphylaxis, *Prehospital Emergency Care*, 2002, 6(1): 67-68.

Web resources

Québec Food Allergy Association (AQAA) (www.aqaa.qc.ca) (French only)
Sécurité allergie (www.securit-allergie.ca/pages/default.asp) (French only)

¹Canadian Society of Allergy and Clinical Immunology (CSACI), *Anaphylaxis in Schools & Other Settings*

²Pediatric Case Reviews, Vol. 3, No. 2, April 2003, page 75

³Regulation respecting the Professional activities that may be engaged in within the framework of pre-hospital emergency services and care (R.Q. c. C-26, r.155.7). Professional Code (R.S.Q. c. C-26), section 94, subsection h***

⁴Canadian Society of Allergy and Clinical Immunology (CSACI), *Anaphylaxis in Schools & Other Settings*

⁵*Circulation*, 2005, Part 10.6: Anaphylaxis, 2005 IV-143-IV-145

⁶*Circulation*, 2005, Part 10.6: Anaphylaxis, 2005 IV-143-IV-145

⁷*Circulation*, 2005, Part 10.6: Anaphylaxis, 2005 IV-143-IV-145

⁸*Pediatric Case Reviews*, Vol. 3, No. 2, April 2003, page 76

www.msss.gouv.qc.ca

